DA
DACHF.US Daicel Corporation
- Market cap
- USD 2.73B
- P/E
- 42.8x
- P/B
- 1.03x
- ROE
- 9.9%
- Dividend yield
- 5.33%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is DACHF.US undervalued?
Graham numberDACHF.US trades 39.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Daicel Corporation fundamental analysis
No fundamental analysis for Daicel Corporation yet.
Daicel Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Daicel Corporation
Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solven…
Full company profileDaicel Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Daicel Corporation annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 440B | 463B | 465B | 413B | 394B | 468B | 538B | 558B | 587B | 583B | 622B |
| Gross Profit | 137B | 137B | 134B | 111B | 111B | 139B | 146B | 159B | 165B | 147B | 165B |
| Operating Income | 64.3B | 58.9B | 51.2B | 29.6B | 31.7B | 50.7B | 47.5B | 62.4B | 61.0B | 42.3B | 56.9B |
| EBITDA | 95.1B | 91.9B | 86.0B | 47.9B | 59.1B | 78.9B | 79.1B | 111B | 109B | 86.0B | 99.8B |
| Net Income | 43.2B | 37.1B | 35.3B | 4.98B | 19.7B | 31.3B | 40.7B | 55.8B | 49.5B | 10.2B | 36.8B |
| EPS | 125 | 108 | 105 | 15 | 65 | 104 | 139 | 198 | 181 | 39 | 144 |
| Balance Sheet | |||||||||||
| Total Assets | 600B | 644B | 655B | 598B | 640B | 699B | 766B | 839B | 814B | 839B | 841B |
| Total Liabilities | 200B | 231B | 232B | 205B | 395B | 419B | 455B | 464B | 439B | 466B | 457B |
| Shareholders' Equity | 370B | 385B | 394B | 363B | 238B | 272B | 295B | 359B | 360B | 358B | 370B |
| Cash & Short-term Investments | 96.9B | 129B | 120B | 81.4B | 91.5B | 90.5B | 93.8B | 73.2B | 65.1B | 69.2B | 55.4B |
| Total Debt | 72.3B | 99.7B | 104B | 89.4B | 268B | 281B | 318B | 300B | 281B | 306B | 286B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 86.2B | 66.9B | 58.5B | 57.2B | 57.9B | 43.0B | 26.8B | 76.7B | 93.4B | 68.3B | - |
| Capital Expenditure | 38.0B | 33.4B | 43.6B | 46.3B | 36.8B | 47.5B | 51.9B | 69.2B | 72.3B | 65.7B | 0.00 |
| Free Cash Flow | 48.2B | 33.5B | 14.9B | 10.9B | 21.1B | -4.48B | -25.1B | 7.52B | 21.1B | 2.53B | - |
| Ratios | |||||||||||
| ROE | 11.7% | 9.6% | 9.0% | 1.4% | 8.3% | 11.5% | 13.8% | 15.6% | 13.7% | 2.9% | 9.9% |
| ROA | 7.2% | 5.8% | 5.4% | 0.8% | 3.1% | 4.5% | 5.3% | 6.7% | 6.1% | 1.2% | 4.4% |
| Net Profit Margin | 9.8% | 8.0% | 7.6% | 1.2% | 5.0% | 6.7% | 7.6% | 10.0% | 8.4% | 1.8% | 5.9% |
| Debt to Equity | 0.20x | 0.26x | 0.26x | 0.25x | 1.13x | 1.03x | 1.08x | 0.84x | 0.78x | 0.86x | 0.78x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Daicel Corporation dividends
- Dividend yield
- 5.33%
- Forward dividend
- 0.50 USD
- Payout ratio
- 156.3%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 16.0B | 61 | 156.3% |
| 2025 | JPY 15.2B | 56 | 30.7% |
| 2024 | JPY 12.9B | 45 | 23.0% |
| 2023 | JPY 10.7B | 36 | 26.2% |
| 2022 | JPY 9.65B | 32 | 30.9% |
| 2021 | JPY 10.4B | 34 | 52.8% |
| 2020 | JPY 10.4B | 32 | 209.1% |
| 2019 | JPY 10.8B | 32 | 30.5% |
| 2018 | JPY 11.4B | 33 | 30.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Daicel Corporation
- Insiders 10.46%
- Institutions 46.85%
- Public & others 42.69%
- Shares outstanding 256M
- Free float 234M
Daicel Corporation company profile
- Company name
- Daicel Corporation
- Ticker
- DACHF.US
- Exchange
- USA Stocks
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 11,034
- Fiscal year end
- March
- Address
- Grand Front Osaka Tower-B, Osaka, Japan, 530-0011
- Phone
- 81 6 7639 7171
- Website
- daicel.com
About Daicel Corporation
Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photoresists, optical lenses, and caprolactone derivatives; functional films and materials used in smartphones, PCs, TVs, and in-vehicle displays, polymers and solvents used in the semiconductor manufacturing process; and lenses used in VR, smartphones and various sensors. In addition, the company offers airbags inflators, pyro-fuses, and gas generators for seat belt pretensioners; acetic acid, acetic acid derivatives, acetate tow, ketene / diketene derivatives, cellulose acetate for LCD optical films, amines, and 1,3-butylene glycol; and reverse osmosis membrane and ultrafiltration membrane products, as well as water treatment systems. Further, it provides Engineering plastics comprising polyacetal, PBT resin, polybutylene terephthalate, polyphenylene sulfide, liquid crystal polymer, and cyclic olefin copolymer; AS resin, acetate plastics, water-soluble polymers, and barrier films for packaging; ABS resins, various polymer alloys, plastic compounds; Polyamide-12 and PEEK resin; and various molded containers. The company's products are used in transportation, electronics, medical care, personal care, lifestyle, everyday life, and environment and energy applications. The company was formerly known as Daicel Chemical Industries, Ltd. and changed its name to Daicel Corporation in October 2011. Daicel Corporation was incorporated in 1919 and is headquartered in Osaka, Japan.
Daicel Corporation management
7- Mr. Yasuhiro SakakiPresident, CEO & Director · born 1962
- Mr. Yoshimi OgawaExecutive Board Chairman · born 1960
- Mr. Kotaro SugimotoSenior Managing Exec. Officer, Head of Corp. Support HQ & Representative Director · born 1960
- Mr. Naotaka KawaguchiSenior Managing Executive Officer, Senior Managing Executive Officer & Director & Director · born 1961
- Seiji YamakadoExecutive Officer & Head of Customer Center
- Toshio ShiwakuSenior Managing Executive Officer & Director · born 1963
- Takashi MiyamotoSenior Managing Executive Officer